Activity of lipoplatin in tumor and in normal cells in vitro

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 983-990

  Arienti, Chiara ^a   Tesei, Anna ^a   Ravaioli, Alberto ^b   Ratta, Marina ^b   Carloni, Silvia ^a   Mangianti, Serena ^b   Ulivi, Paola ^a   Nicoletti, Stefania ^b   Amadori, Dino ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b Infermi Hospital   (Italy)

Author keywords

ERCC1; Lipoplatin; LRP; MDR 1; Non small cell lung cancer; Renal cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; LIPOPLATIN; LUNG RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; DRUG SENSITIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50;

EID: 54249112039     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283114fb2     Document Type: Article

References (34)

1. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100:704-713.
2. Solomon B, Mitchell JD, Bunn PA Jr. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park) 2005; 19:1685-1697.
3. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73:994-1007.
4. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992; 69:203-207.
5. Vermorken JB, Kapteijn TS, Hart AA, Pineto HM. Ototoxicity of cis diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19:53-58.
6. Sfikakis PP, Souliotis VL, Katsilambros N, Markakis K, Vaiopoulos G, Tsokos GC, et al. Downregulation of interleukin-2 and α-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. Clin Immunol Immunopathol 1996; 79:43-49.
7. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10:1663-1682.
8. Coluccia M, Natile G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med Chem 2007; 7:111-123.
9. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34:1522-1534.
10. Brabec V, Kasparkova J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 2005; 8:131-146.
11. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-584.
12. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 2002; 5:147-161.
13. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-7279.
14. Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 2004; 24:2193-2200.
15. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12:3-12.
16. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 2005; 13:589-595.
17. Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006; 15:1201-1204.
18. Stathopoulos GP, Boulikas T, Rigatos SK, Deliconstantinos G, Stathopoulos JG, Darli E, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced cancer patient. Phase I-II study [Abstract 90P]. Ann Oncol 2002; 13(Suppl):S25.
19. Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemothrapy and antiangiogenesis drug. Cancer Ther 2007; 5:349-376.
20. Jehn CF, Boulikas T, Kourvetaris A, Possinger K, Lüftner D. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007; 27:471-475.
21. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25:3031-3039.
22. Gasperi-Campani A, Roncuzzi L, Ricotti L, Lenzi L, Gruppioni R, Sensi A, et al. Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines. Cancer Genet Cytogenet 1998; 107:11-20.
23. + cells mobilized into peripheral blood. Bone Marrow Transplant 1998; 22(Suppl):S47-S50.
24. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
25. Motta MR, Mangianti S, Rizzi S, Ratta M, Campanini E, Fortuna A, et al. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblasts leukemia patients: preclinical studies. Exp Hematol 1997; 25:1261-1269.
26. Zoli W, Ricotti L, Tesei A, Ulivi P, Gasperi Campani A, Fabbri F, et al. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 2004; 10:1500-1507.
27. Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, et al. Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep 2006; 15:645-652.
28. Berger W, Elbling L, Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000; 88:293-300.
29. Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, Pfützner A, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anti-Cancer Drugs 2006; 17:1041-1044.
30. Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007; 7:261-268.
31. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991.
32. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2:902-906.
33. Danzinger S, Filipits M. Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC). Wien Med Wochenschr 2007; 157:554-561.
34. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007; 33:565-577.